Literature DB >> 6163662

Character and meaning of quasi-morphine withdrawal phenomena elicited by methylxanthines.

H O Collier, N J Cuthbert, D L Francis.   

Abstract

A quasi-morphine withdrawal syndrome (QMWS) is a pattern of behavior closely resembling the true withdrawal syndrome in the opiate-dependent animal, which can be elicited acutely by a nonopiate drug in an opiate-naive animal. The main criteria proposed for the QMWS, in addition to its resembling the true withdrawal syndrome, are that the effects of opiates and of opiate antagonists on the QMWS should parallel those on true opiate withdrawal. Drugs that wholly or largely fulfill these criteria are 3-isobutyl-1-methylxanthine (IBMX), theophylline, caffeine, ICI 63197, and RO 201724. From the evidence given, it is concluded that these drugs act by inhibiting brain cyclic AMP phosphodiesterase, thus raising the level of cyclic AMP in appropriate neurons. These findings are consistent with the view that the molecular mechanisms of opiate dependence is the hypertrophy of a neuronal cyclic AMP system in compensation for the inhibition by opiate of an adenylate cyclase. Our studies and those of others suggest that: a) very rapid tests for opiate activity and for addictive liability can be devised by use of IBMX; b) opiates may be used clinically to counter poisoning by caffeine or theophylline; and c) a relationship may exist between caffeine consumption and opiate addiction.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6163662

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  10 in total

1.  The serotonin2 antagonist ritanserin blocks quasi-morphine withdrawal at a time when mianserin is no longer effective.

Authors:  B S Neal; S B Sparber
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 2.  Second messenger and protein phosphorylation mechanisms underlying opiate addiction: studies in the rat locus coeruleus.

Authors:  X Guitart; E J Nestler
Journal:  Neurochem Res       Date:  1993-01       Impact factor: 3.996

3.  Modification of quasi-morphine withdrawal with serotonin agonists and antagonists: evidence for a role of serotonin in the expression of opiate withdrawal.

Authors:  M S Kleven; S B Sparber
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Icilin-evoked behavioral stimulation is attenuated by alpha₂-adrenoceptor activation.

Authors:  Jae Kim; Alan Cowan; Renata Lisek; Natalie Raymondi; Aaron Rosenthal; Daniel D Hirsch; Scott M Rawls
Journal:  Brain Res       Date:  2011-04-12       Impact factor: 3.252

5.  Long-term effects of neonatal exposure to isobutylmethylxanthine. I. Retardation of learning with antagonism by mianserin.

Authors:  B S Neal; S B Sparber
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

6.  Long-term effects of neonatal exposure to isobutylmethylxanthine. II. Attenuation of acute morphine withdrawal in mature rats.

Authors:  B S Neal; R B Messing; S B Sparber
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

7.  Nalfurafine, the kappa opioid agonist, inhibits icilin-induced wet-dog shakes in rats and antagonizes glutamate release in the dorsal striatum.

Authors:  Jennifer L Werkheiser; Scott M Rawls; Alan Cowan
Journal:  Neuropharmacology       Date:  2006-12-05       Impact factor: 5.250

8.  The opiate quasiwithdrawal syndrome in rhesus monkeys: comparison of naloxone-precipitated withdrawal to effects of cholinergic agents.

Authors:  J L Katz; R J Valentino
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

9.  Species differences in behavioural effects of rolipram and other adenosine cyclic 3H, 5H-monophosphate phosphodiesterase inhibitors.

Authors:  H Wachtel
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

10.  Absence of quasi-morphine withdrawal syndrome in adenosine A2A receptor knockout mice.

Authors:  Ainhoa Bilbao; Andrea Cippitelli; Ana Belén Martín; Noelia Granado; Oscar Ortiz; Erwan Bezard; Jiang-Fan Chen; Miguel Navarro; Fernando Rodríguez de Fonseca; R Moratalla
Journal:  Psychopharmacology (Berl)       Date:  2006-02-10       Impact factor: 4.530

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.